

GLAXOSMITHKLINE PLC

Form 6-K

July 27, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 27 July 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Transaction notification

The Company changed suppliers in respect of Long-Term Incentives administration in May 2018. On 26 July 2018, Ordinary Shares and American Depositary Shares (ADS) held by Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) in nominee accounts were transferred from the previous administrator to the new administrator.

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument
 

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
  - b) Nature of the transaction
 

Transfer of Ordinary Shares between accounts.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.00	121,966.031
  - d) Aggregated information
 

n/a (single transaction)
  - e) Date of the transaction
 

2018-07-26
  - f) Place of the transaction
 

Off market

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R G Connor
  - b) Position/status President, Global Manufacturing & Supply
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

Ordinary shares of 25 pence  
 each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

Transfer of Ordinary Shares  
 between accounts.

- b) Nature of the transaction

No change in beneficial  
 ownership.

- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £0.00    | 3,361.333 |

- d) Aggregated information n/a (single transaction)

- Aggregated volume Price

- e) Date of the transaction 2018-07-26

- f) Place of the transaction Off market

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr L Debruyne  
 b) Position/status President, Global Vaccines  
 c) Initial notification/  
 amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

- Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

Ordinary shares of 25 pence  
 each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

Transfer of Ordinary Shares  
 between accounts.

- b) Nature of the transaction

No change in beneficial  
 ownership.

- c) Price(s) and volume(s)
- | Price(s) | Volume(s)  |
|----------|------------|
| £0.00    | 88,000.060 |

- d) Aggregated information n/a (single transaction)
- Aggregated volume Price
- e) Date of the transaction 2018-07-26
- f) Place of the transaction Off market

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S Dingemans
- b) Position/status Chief Financial Officer
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

Transfer of Ordinary Shares between accounts.

b) Nature of the transaction

No change in beneficial ownership.

- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.00	83,440.728

d) Aggregated information n/a (single transaction)

- Aggregated volume Price
- e) Date of the transaction 2018-07-26
- f) Place of the transaction Off market

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hirons
- b) Position/status SVP, Global Ethics & Compliance
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

Ordinary shares of 25 pence  
 each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

Transfer of Ordinary Shares  
 between accounts.

- b) Nature of the transaction

No change in beneficial  
 ownership.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	24,588.491

- d) Aggregated information  
 Aggregated volume Price

n/a (single transaction)

- e) Date of the transaction

2018-07-26

- f) Place of the transaction

Off market

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hiron  
 b) Position/status SVP, Global Ethics &  
 Compliance  
 c) Initial notification/  
 amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

American Depositary Shares  
 ('ADSs')

- a) Description of the financial instrument ISIN: US37733W1053

Transfer of ADSs between  
 accounts.

- b) Nature of the transaction

No change in beneficial  
 ownership.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
----------	-----------

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

\$0.00 1,528.812

- d) Aggregated information n/a (single transaction)
- e) Date of the transaction 2018-07-26
- f) Place of the transaction Off market

Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr B McNamara
- b) Position/status CEO, GSK Consumer Healthcare
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depository Shares ('ADSs')  
ISIN: US37733W1053

Transfer of ADSs between accounts.

b) Nature of the transaction

No change in beneficial ownership.

- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
\$0.00	36,712.903

- d) Aggregated information n/a (single transaction)
- e) Date of the transaction 2018-07-26
- f) Place of the transaction Off market

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

Ordinary shares of 25 pence  
 each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

Transfer of Ordinary Shares  
 between accounts.

- b) Nature of the transaction

No change in beneficial  
 ownership.

- c) Price(s) and volume(s)
- | Price(s) | Volume(s)   |
|----------|-------------|
| £0.00    | 154,521.108 |

- d) Aggregated information n/a (single transaction)

- e) Aggregated volume Price

- e) Date of the transaction 2018-07-26

- f) Place of the transaction Off market

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas  
 b) Position/status SVP, Human Resources

- c) Initial notification/  
 amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

- Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

Ordinary shares of 25 pence  
 each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

Transfer of Ordinary Shares  
 between accounts.

- b) Nature of the transaction

No change in beneficial  
 ownership.

- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
|----------|-----------|

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£0.00 97,974.175

- d) Aggregated information n/a (single transaction)
- e) Date of the transaction 2018-07-26
- f) Place of the transaction Off market

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs K Thomson
- b) Position/status PCA of Mr P C Thomson  
(President, Global Affairs)
- c) Initial notification/  
amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

Transfer of Ordinary Shares between accounts.

b) Nature of the transaction

No change in beneficial ownership.

- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.00	10,122.428

d) Aggregated information n/a (single transaction)

- e) Date of the transaction 2018-07-26
- f) Place of the transaction Off market

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson
- b) Position/status President, Global Affairs
- c) Initial notification/  
amendment Initial Notification

2.



Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

Transfer of Ordinary Shares between accounts.

- b) Nature of the transaction

No change in beneficial ownership.

- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.00	16,702.991

- d) Aggregated information n/a (single transaction)
- e) Aggregated volume Price

- e) Date of the transaction 2018-07-26

- f) Place of the transaction Off market

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D E Troy
- b) Position/status SVP & General Counsel

- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

American Depositary Shares ('ADSs')

- a) Description of the financial instrument ISIN: US37733W1053

Transfer of ADSs between accounts.

- b) Nature of the transaction

No change in beneficial ownership.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	\$0.00	184,542.810
d) Aggregated information Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2018-07-26	
f) Place of the transaction	Off market	

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 27,2018

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc